RPTX Insider Trading Activity and SEC Form 4 Filings
RPTX insider trading summary
No open-market insider purchases or sales of Repare Therapeutics Inc. (RPTX) have been reported on SEC Form 4 in the past 12 months.
Latest RPTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 12, 2025 | Michael Zinda | EVP, Chief Scientific Officer | Sell | $6K (5,611 @ $1.14) |
| Mar 12, 2025 | Maria Koehler | EVP, Chief Medical Officer | Sell | $4K (3,596 @ $1.14) |
| Mar 12, 2025 | Steve Forte | EVP, Chief Financial Officer | Sell | $8K (6,884 @ $1.14) |
| Mar 12, 2025 | Lloyd Mitchell Segal | President and CEO | Sell | $24K (21,179 @ $1.14) |
| Apr 1, 2024 | Steve Forte | EVP, Chief Financial Officer | Sell | $4K (789 @ $4.61) |
| Apr 1, 2024 | Michael Zinda | EVP, Chief Scientific Officer | Sell | $2K (410 @ $4.66) |
| Apr 1, 2024 | Maria Koehler | EVP, Chief Medical Officer | Sell | $1K (300 @ $4.66) |
| Apr 1, 2024 | Lloyd Mitchell Segal | President and CEO | Sell | $12K (2,491 @ $4.63) |
| Mar 28, 2024 | Lloyd Mitchell Segal | President and CEO | Sell | $12K (2,650 @ $4.62) |
| Mar 28, 2024 | Michael Zinda | EVP, Chief Scientific Officer | Sell | $2K (450 @ $4.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.